Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of 14C-TA-8995 in Healthy Males
NCT02408055Phase 1Completed
- Sponsor
- Xention Ltd.
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of obicetrapib in dyslipidemia, sponsored by Xention Ltd. Primary endpoints: Area Under the Curve of TA-8995 at 35 days, Mass balance recovery of total radioactivity from excreta at 35 days and 3 more. Started Jun 2015; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02408055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02408055.